Spots Global Cancer Trial Database for Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)
Official Title: A Phase II Randomized, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of Bicalutamide With or Without Deforolimus (Ridaforolimus) in Men With Asymptomatic, Metastatic Castrate-resistant Prostate Cancer
Study ID: NCT00777959
Conditions
Study Description
Brief Summary: This study will look to see if the combination of ridaforolimus and bicalutamide works better than placebo and bicalutamide in men with prostate cancer.
Detailed Description: Ridaforolimus (MK8669/AP23573) was also known as deforolimus until May 2009.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Contact Details
Name: Medical Monitor
Affiliation: Merck Sharp & Dohme LLC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
